Bristol-Myers Squibb

2018 Healthcare And Biotech Outlook
2018 Healthcare And Biotech Outlook
Seeking Alpha
AbbVie
Abbott Labs
Amgen
Allergan
AstraZeneca
Gilead Sciences
Bristol-Myers Squibb
Flag link:
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Yahoo/Reuters
Bristol-Myers Squibb
taxes
Flag link:
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Flag link:
Top 10 stories that had pharma execs talking
Top 10 stories that had pharma execs talking
Biopharma Dive
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Flag link:
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Bristol-Myers Squibb
AstraZeneca
Opdivo
Lynparza
China
Flag link:
Oncology business to keep leading pharma market in 2018
Oncology business to keep leading pharma market in 2018
GoinPharma
oncology
Merck
Bristol-Myers Squibb
Pfizer
Roche
Flag link:
3 Promising Cancer Immunotherapies to Watch in 2018
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Endpoints
Bristol-Myers Squibb
Opdivo
Ono Pharmaceutical
ONO-4578
immuno-oncology
drug development
Flag link:
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Yahoo/Zacks.com
Bristol-Myers Squibb
Opdivo
clinical trials
Docetaxel
China
Flag link:
Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Endpoints
Bristol-Myers Squibb
Opdivo
China
Docetaxel
lung cancer
Flag link:
Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab
Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab
Endpoints
Innate Pharma
Bristol-Myers Squibb
lirilumab
acute myeloid leukemia
Flag link:
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas
Fierce Pharma
drug launches
Keytruda
Harvoni
Opdivo
Merck
Bristol-Myers Squibb
Gilead Sciences
Flag link:
Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Biogen
M&A
Flag link:
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
NASDAQ.com
Nektar
NKTR-214
Opdivdo
Bristol-Myers Squibb
Flag link:
Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
Endpoints
Bristol-Myers Squibb
IDO1
BMS-986205
Incyte
bladder cancer
cervical cancer
Flag link:
The Only 3 Big Pharma Companies Growing Market Share
The Only 3 Big Pharma Companies Growing Market Share
Motley Fool
Bristol-Myers Squibb
Opdivo
Shire
Celgene
Flag link:
Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer
Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
kidney cancer
Flag link:
Bristol-Myers, J&J sink cash into a new $95M European biotech fund
Bristol-Myers, J&J sink cash into a new $95M European biotech fund
Endpoints
JNJ
Bristol-Myers Squibb
Europe
biotech
BioGeneration Ventures
Flag link:
Why What’s Bad for Merck Is Good For Bristol-Myers
Why What’s Bad for Merck Is Good For Bristol-Myers
Barron's
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Europe
Flag link:

Pages